TD Cowen Maintains Buy on Insmed, Raises Price Target to $98
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Ritu Baral maintains a Buy rating on Insmed (NASDAQ:INSM) and raises the price target from $75 to $98.
August 09, 2024 | 5:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen analyst Ritu Baral maintains a Buy rating on Insmed and raises the price target from $75 to $98.
The raised price target from $75 to $98 by a reputable analyst at TD Cowen is a positive signal for investors, indicating confidence in Insmed's future performance. This is likely to result in a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100